Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to August 2014

Fight Immune Decline With Reishi

August 2014

By Walter Thompson

Summary

Chinese medical practitioners have long recognized the value of the medicinal Reishi mushroom, and used it to promote healthy, long lives in their patients. Modern science has revealed the virtual pharmacy contained inside these mushrooms, which contain a broad array of biologically active molecules.

Chief among the benefits of Reishi mushrooms is their ability to counteract immunosenescence, the aging and gradual loss of immune function. Immunosenescence raises risk for infection, cancer, and cardiovascular disease.

Studies now convincingly demonstrate the value of Reishi mushroom extracts in combating the very infections that most prominently threaten our health as we age, by boosting functions of immune system cells that identify, track, and destroy infectious agents. Similar immune-boosting effects from Reishi extracts help the immune system recognize the abnormal molecular patterns that mark cancer cells, helping to eliminate them before they mature into malignant tumors. Reishi extracts also act on the other extreme of the immune system, helping to end the overactive inflammation that contributes to cardiovascular disease.

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.

References

  1. Martorana A, Bulati M, Buffa S, et al. Immunosenescence, inflammation and Alzheimer’s disease. Longev Healthspan. 2012 Nov 1;1:8. eCollection 2012.
  2. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006 Feb;83(2):456S-60S.
  3. Aw D, Silva AB, Palmer DB.Immunosenescence: emerging challenges for an ageing population. Immunology. 2007 Apr;120(4):435-46.
  4. Sidler C, Wóycicki R, Ilnytskyy Y, Metz G, Kovalchuk I, Kovalchuk O. Immunosenescence is associated with altered gene expression and epigenetic regulation in primary and secondary immune organs. Front Genet. 2013 Oct 18;4:211.
  5. Palmer DB. The effect of age on thymic function. Front Immunol. 2013 Oct 7;4:316.
  6. Sanodiya BS, Thakur GS, Baghel RK, Prasad GB, Bisen PS.Ganoderma lucidum: a potent pharmacological macrofungus. Curr Pharm Biotechnol. 2009 Dec;10(8):717-42.
  7. Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D. Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr Cancer. 2004;49(2):209-16.
  8. Zheng S, Jia Y, Zhao J, Wei Q, Liu Y. Ganoderma lucidum polysaccharides eradicates the blocking effect of fibrinogen on NK cytotoxicity against melanoma cells. Oncol Lett. 2012 Mar;3(3):613-6.
  9. Yue GG, Fung KP, Tse GM, Leung PC, Lau CB. Comparative studies of various ganoderma species and their different parts with regard to their antitumor and immunomodulating activities in vitro. J Altern Complement Med. 2006 Oct;12(8):777-89.
  10. Guo L, Xie J, Ruan Y, et al. Characterization and immunostimulatory activity of a polysaccharide from the spores of Ganoderma lucidum. Int Immunopharmacol. 2009 Sep;9(10):1175-82.
  11. Chang SS, Zhou D, Meng GL, et al. Effect of Ganoderma lucidum polysaccharides on oxidative stress of hyperlipidemic fatty liver in rats. Zhongguo Zhong Yao Za Zhi. 2012 Oct;37(20):3102-6.
  12. Chen WQ, Luo SH, Ll HZ, Yang H. Effects of ganoderma lucidum polysaccharides on serum lipids and lipoperoxidation in experimental hyperlipidemic rats. Zhongguo Zhong Yao Za Zhi. 2005 Sep;30(17):1358-60.
  13. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007 May;117(5):1137-46.
  14. Available at: http://www.merckmanuals.com/home/immune_disorders/
    biology_of_the_immune_system/overview_of_the_immune_system.html.
    Accessed May 14 , 2014.
  15. Craven DE, Steger KA. Nosocomial pneumonia in the intubated patient. New concepts on pathogenesis and prevention. Infect Dis Clin North Am. 1989 Dec;3(4):843-66.
  16. Paradisi F, Corti G. Antibiotic resistance in community-acquired pulmonary pathogens. Semin Respir Crit Care Med. 2000;21(1):33-43.
  17. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31(2):578-85.
  18. McElhaney JE, Zhou X, Talbot HK, et al. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine. 2012 Mar 9;30(12):2060-7.
  19. Jackson LA, Baxter R, Naleway AL, Belongia EA, Baggs J. Patterns of pneumococcal vaccination and revaccination in elderly and non-elderly adults: a Vaccine Safety Datalink study. BMC Infect Dis. 2009 Mar 25;9:37.
  20. Andrews RM. Assessment of vaccine coverage following the introduction of a publicly funded pneumococcal vaccine program for the elderly in Victoria, Australia. Vaccine . 2005 Apr 15;23(21):2756-61.
  21. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis . 2008 May;14(5):727-33.
  22. Dorrington MG, Bowdish DM. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol. 2013 Jun 28;4:171.
  23. Bonnal C, Desaint C, Raynaud-Simon A, et al. The vaccination of older adults: a challenge for the future! Presse Med. 2013 Mar;42(3):318-26.
  24. Fulop T, Larbi A, et al. Aging, immunity, and cancer. Discov Med. 2011 Jun;11(61):537-50.
  25. Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S272-83.
  26. Salvioli S, Monti D, Lanzarini C, et al. Immune system, cell senescence, aging and longevity—inflamm-aging reappraised. Curr Pharm Des. 2013;19(9):1675-9.
  27. Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000 Jun;908:244-54.
  28. Zanni F, Vescovini R, Biasini C, et al. Marked increase with age of type 1 cytokines within memory and effector/cytotoxic CD8+ T cells in humans: a contribution to understand the relationship between inflammation and immunosenescence. Exp Gerontol. 2003 Sep;38(9):981-7.
  29. Xu Z, Chen X, Zhong Z, Chen L, Wang Y. Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities. Am J Chin Med. 2011;39(1):15-27.
  30. Cao LZ, Lin ZB. Regulation on maturation and function of dendric cells by Ganoderma lucidum polysaccharides. Immunol Lett. 2002;83(3):163-9.
  31. Hijikata Y, Yasuhara A, Sahashi Y. Effect of an herbal formula containing Ganoderma lucidum on reduction of herpes zoster pain: a pilot clinical trial. Am J Chin Med. 2005;33(4):517-23.
  32. Eo SK, Kim YS, Lee CK, Han SS. Possible mode of antiviral activity of acidic protein bound polysaccharide isolated from Ganoderma lucidum on herpes simplex viruses. J Ethnopharmacol. 2000 Oct;72(3):475-81.
  33. Liu J, Yang F, Ye LB, et al. Possible mode of action of antiherpetic activities of a proteoglycan isolated from the mycelia of Ganoderma lucidum in vitro. J Ethnopharmacol. 2004 Dec;95(2-3):265-72.
  34. Kim YS, Eo SK, Oh KW, Lee C, Han SS. Antiherpetic activities of acidic protein bound polysacchride isolated from Ganoderma lucidum alone and in combinations with interferons. J Ethnopharmacol. 2000 Oct;72(3):451-8.
  35. Oh KW, Lee CK, Kim YS, Eo SK, Han SS. Antiherpetic activities of acidic protein bound polysacchride isolated from Ganoderma lucidum alone and in combinations with acyclovir and vidarabine. J Ethnopharmacol. 2000 Sep;72(1-2):221-7.
  36. Hijikata Y, Yamada S. Effect of Ganoderma lucidum on postherpetic neuralgia. Am J Chin Med. 1998;26(3-4):375-81.
  37. Li Z, Liu J, Zhao Y. Possible mechanism underlying the antiherpetic activity of a proteoglycan isolated from the mycelia of Ganoderma lucidum in vitro. J Biochem Mol Biol. 2005 Jan 31;38(1):34-40.
  38. Wang L, Hou Y. Determination of trace elements in anti-influenza virus mushrooms. Biol Trace Elem Res. 2011 Dec;143(3):1799-807.
  39. Beck MA, Nelson HK, Shi Q, et al. Selenium deficiency increases the pathology of an influenza virus infection. FASEB J. 2001;15(8):1481-3.
  40. Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev. 2011;(2):CD001364.
  41. Iwatsuki K, Akihisa T, Tokuda H, et al. Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation. J Nat Prod. 2003 Dec;66(12):1582-5.
  42. Akihisa T, Nakamura Y, Tagata M, et al. Anti-inflammatory and anti-tumor-promoting effects of triterpene acids and sterols from the fungus Ganoderma lucidum. Chem Biodivers. 2007 Feb;4(2):224-31.
  43. Hjalgrim H. On the aetiology of Hodgkin lymphoma. Dan Med J. 2012 Jul;59(7):B4485. Review. PubMed PMID: 22759852.
  44. Engels EA. Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidem Biomar. 2007 Mar;16(3):401-4.
  45. Li Y, Yang Y, Fang L, Zhang Z, Jin J, Zhang K. Anti-hepatitis activities in the broth of Ganoderma lucidum supplemented with a Chinese herbal medicine. Am J Chin Med. 2006;34(2):341-9.
  46. Li YQ, Wang SF. Anti-hepatitis B activities of ganoderic acid from Ganoderma lucidum. Biotechnol Lett. 2006 Jun;28(11):837-41.
  47. Lu YZ, Wu XX, Chen S, et al. Effectiveness of Ganoderma lucidum preparation in treating simian acquired immune deficiency syndrome. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Jun;33(3):318-24.
  48. Hua KF, Hsu HY, Chao LK, et al. Ganoderma lucidum polysaccharides enhance CD14 endocytosis of LPS and promote TLR4 signal transduction of cytokine expression. J Cell Physiol. 2007 Aug;212(2):537-50.
  49. Lin CY, Chen YH, Lin CY, et al. Ganoderma lucidum polysaccharides attenuate endotoxin-induced intercellular cell adhesion molecule-1 expression in cultured smooth muscle cells and in the neointima in mice. J Agric Food Chem. 2010 Sep 8;58(17):9563-71.
  50. Wang SH, Liang CJ, Weng YW, et al. Ganoderma lucidum polysaccharides prevent platelet-derived growth factor-stimulated smooth muscle cell proliferation in vitro and neointimal hyperplasia in the endothelial-denuded artery in vivo. J Cell Physiol. 2012 Aug;227(8):3063-71.
  51. Chitturi S. Treatment options for nonalcoholic Fatty liver disease. Therap Adv Gastroenterol. 2008 Nov;1(3):173-89.
  52. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009 Jan;13(1):9-19.
  53. Hajjaj H, Mace C, Roberts M, Niederberger P, Fay LB. Effect of 26-oxygenosterols from Ganoderma lucidum and their activity as cholesterol synthesis inhibitors. Appl Environ Microbiol. 2005 Jul;71(7):3653-8.
  54. Kim SD. Isolation and structure determination of a cholesterol esterase inhibitor from Ganoderma lucidum. J Microbiol Biotechnol. 2010 Nov;20(11):1521-3.
  55. Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014 Mar 20. pii: S1043-6618(14)00025-5.
  56. Chu TT, Benzie IF, Lam CW, Fok BS, Lee KK, Tomlinson B. Study of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial. Br J Nutr. 2012 Apr;107(7):1017-27.
  57. Seto SW, Lam TY, Tam HL, et al. Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine. 2009 May;16(5):426-36.
  58. Teng BS, Wang CD, Zhang D, et al. Hypoglycemic effect and mechanism of a proteoglycan from ganoderma lucidum on streptozotocin-induced type 2 diabetic rats. Eur Rev Med Pharmacol Sci. 2012 Feb;16(2):166-75.
  59. Zheng J, Yang B, Yu Y, Chen Q, Huang T, Li D. Ganoderma lucidum polysaccharides exert anti-hyperglycemic effect on streptozotocin-induced diabetic rats through affecting beta-cells. Comb Chem High Throughput Screen. 2012 Aug;15(7):542-50.
  60. Jiang J, Slivova V, Valachovicova T, Harvey K, Sliva D. Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3. Int J Oncol. 2004 May;24(5):1093-9.
  61. Boh B. Ganoderma lucidum: a potential for biotechnological production of anti-cancer and immunomodulatory drugs. Recent Pat Anticancer Drug Discov. 2013 Sep;8(3):255-87.
  62. Liu RM, Zhong JJ. Ganoderic acid Mf and S induce mitochondria mediated apoptosis in human cervical carcinoma HeLa cells. Phytomedicine. 2011 Mar 15;18(5):349-55.
  63. Zamai L, Ponti C, Mirandola P, et al. NK cells and cancer. J Immunol. 2007 Apr 1;178(7):4011-6.
  64. Lin SB, Li CH, Lee SS, Kan LS. Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest. Life Sci. 2003 Apr 11;72(21):2381-90.
  65. Wang J, Wang Y, Liu X, Yuan Y, Yue T. Free radical scavenging and immunomodulatory activities of Ganoderma lucidum polysaccharides derivatives. Carbohydr Polym . 2013 Jan 2;91(1):33-8.
  66. Nonaka Y, Shibata H, Nakai M, et al. Anti-tumor activities of the antlered form of Ganoderma lucidum in allogeneic and syngeneic tumor-bearing mice. Biosci Biotechnol Biochem. 2006 Sep;70(9):2028-34.
  67. Pang X, Chen Z, Gao X, et al. Potential of a novel polysaccharide preparation (GLPP) from Anhui-grown Ganoderma lucidum in tumor treatment and immunostimulation. J Food Sci. 2007 Aug;72(6):S435-42.
  68. Chen HS, Tsai YF, Lin S, et al. Studies on the immuno-modulating and anti-tumor activities of Ganoderma lucidum (Reishi) polysaccharides. Bioorg Med Chem. 2004 Nov 1;12(21):5595-601.
  69. Fukuzawa M, Yamaguchi R, Hide I, et al. Possible involvement of long chain fatty acids in the spores of Ganoderma lucidum (Reishi Houshi) to its anti-tumor activity. Biol Pharm Bull. 2008 Oct;31(10):1933-7.
  70. Gao P, Hirano T, Chen Z, Yasuhara T, Nakata Y, Sugimoto A. Isolation and identification of C-19 fatty acids with anti-tumor activity from the spores of Ganoderma lucidum (reishi mushroom). Fitoterapia. 2012 Apr;83(3):490-9.
  71. Katagata Y, Sasaki F. Antiproliferative activity of extracts prepared from three species of Reishi on cultured human normal and tumor cell lines. Mol Med Rep. 2010 Jan-Feb;3(1):179-84.
  72. Zhao S, Ye G, Fu G, Cheng JX, Yang BB, Peng C. Ganoderma lucidum exerts anti-tumor effects on ovarian cancer cells and enhances their sensitivity to cisplatin. Int J Oncol. 2011 May;38(5):1319-27.
  73. Martinez-Montemayor MM, Acevedo RR, Otero-Franqui E, Cubano LA, Dharmawardhane SF. Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer. Nutr Cancer. 2011;63(7):1085-94.
  74. Cao QZ, Lin ZB. Antitumor and anti-angiogenic activity of Ganoderma lucidum polysaccharides peptide. Acta Pharmacol Sin. 2004 Jun;25(6):833-8.
  75. Weng CJ, Yen GC. The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Clin Exp Metastasis. 2010 May;27(5):361-9.
  76. Jiang J, Slivova V, Sliva D. Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol. 2006 Sep;29(3):695-703.
  77. Jiang J, Grieb B, Thyagarajan A, Sliva D. Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. Int J Mol Med. 2008 May;21(5):577-84.
  78. Silva D, Labarrere C, Slivova V, Sedlak M, Lloyd FP Jr, Ho NW. Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun. 2002 Nov 8;298(4):603-12.
  79. Wu G, Qian Z, Guo J, et al. Ganoderma lucidum extract induces G1 cell cycle arrest, and apoptosis in human breast cancer cells. Am J Chin Med. 2012;40(3):631-42.
  80. Lu H, Song J, Jia XB, Feng L. Antihepatoma activity of the acid and neutral components from Ganoderma lucidum. Phytother Res. 2012 Sep;26(9):1294-300.
  81. Wu GS, Lu JJ, Guo JJ, et al. Ganoderic acid DM, a natural triterpenoid, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Fitoterapia. 2012 Mar;83(2):408-14.
  82. Hu H, Ahn NS, Yang X, Lee YS, Kang KS. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer. 2002 Nov 20;102(3):250-3.
  83. Batbayar S, Kim MJ, Kim HW. Medicinal mushroom Lingzhi or Reishi, Ganoderma lucidum (W.Curt.:Fr.) P. Karst., beta-glucan induces Toll-like receptors and fails to induce inflammatory cytokines in NF-kappaB inhibitor-treated macrophages. Int J Med Mushrooms. 2011;13(3):213-25.
  84. Chen NH, Liu JW, Zhong JJ. Ganoderic acid T inhibits tumor invasion in vitro and in vivo through inhibition of MMP expression. Pharmacol Rep. 2010 Jan-Feb;62(1):150-63.
  85. Weng CJ, Chau CF, Yen GC, Liao JW, Chen DH, Chen KD. Inhibitory effects of ganoderma lucidum on tumorigenesis and metastasis of human hepatoma cells in cells and animal models. J Agric Food Chem. 2009 Jun 10;57(11):5049-57.
  86. Li F, Wang Y, Wang X, Li J, Cui H, Niu M. Ganoderic acids suppress growth and angiogenesis by modulating the NF-κB signaling pathway in breast cancer cells. Int J Clin Pharmacol Ther. 2012 Oct;50(10):712-21.
  87. Perentes JY, Kirkpatrick ND, Nagano S, et al. Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors. Cancer Res. 2011 Jul 1;71(13):4527-38.
  88. Liu J, Shiono J, Shimizu K, Kukita A, Kukita T, Kondo R. Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2154-7.
  89. Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. A water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia suppresses azoxymethane-induction of colon cancers in male F344 rats. Oncol Rep. 2003 Mar-Apr;10(2):375-9.
  90. Sliva D, Loganathan J, Jiang J, et al. Mushroom Ganoderma lucidum prevents colitis-associated carcinogenesis in mice. PLoS One. 2012;7(10):e47873.
  91. Kashimoto N, Hayama M, Kamiya K, Watanabe H. Inhibitory effect of a water-soluble extract from the culture medium of Ganoderma lucidum (Rei-shi) mycelia on the development of pulmonary adenocarcinoma induced by N-nitrosobis (2-hydroxypropyl) amine in Wistar rats. Oncol Rep. 2006 Dec;16(6):1181-7.
  92. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007 Jun;35(4):495-516.
  93. Available at: http://www.britannica.com/EBchecked/topic/92230/cancer/224769/Apoptosis-and-cancer-development. Accessed May 14, 2014.
  94. Yuen JW, Gohel MD, Ng CF. The differential immunological activities of Ganoderma lucidum on human pre-cancerous uroepithelial cells. J Ethnopharmacol. 2011 Jun 1;135(3):711-8.
  95. Thyagarajan A, Zhu J, Sliva D. Combined effect of green tea and Ganoderma lucidum on invasive behavior of breast cancer cells. Int J Oncol. 2007 Apr;30(4):963-9.
  96. Thyagarajan A, Jiang J, Hopf A, Adamec J, Sliva D. Inhibition of oxidative stress-induced invasiveness of cancer cells by Ganoderma lucidum is mediated through the suppression of interleukin-8 secretion. Int J Mol Med. 2006 Oct;18(4):657-64.
  97. Suarez-Arroyo IJ, Rosario-Acevedo R, Aguilar-Perez A, et al. Anti-tumor effects of Ganoderma lucidum (reishi) in inflammatory breast cancer in in vivo and in vitro models. PLoS One. 2013;8(2):e57431.
  98. Mohamed M, Al-Raawi D, Sabet SF, El-Shinnawi M. Inflammatory breast cancer: New factors contribute to disease etiology: Review. Journal of Advanced Research. Available online June 14, 2013.
  99. Kimura Y, Taniguchi M, Baba K. Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: mechanism of action and isolation of an active substance. Anticancer Res. 2002 Nov-Dec;22(6a):3309-18.
  100. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003 Aug;32(3):201-15.
  101. Oka S, Tanaka S, Yoshida S, et al. A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima J Med Sci. 2010 Mar;59(1):1-6.